Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 10/20 | 0.52 |
| ▸ | KDR | P35968 | 10/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611547 | 0.90 | EPHA2 (0.50) | EPHA2KDREPHB4ENPP1ERBB2 | |
| SCHEMBL3133518 | 0.90 | EPHA2 (0.50) | EPHA2KDREPHB4ENPP1ERBB2 | |
| SCHEMBL3132212 | 0.90 | EPHA2 (0.50) | EPHA2KDREPHB4ENPP1ERBB2 | |
| SCHEMBL5214519 | 0.84 | ENPP1 (0.52) | EPHA2KDREPHB4ENPP1ERBB2 | |
| SCHEMBL664787 | 0.78 | EPHA2 (0.52) | EPHA2KDREPHB4ENPP1ERBB2 | |
| SCHEMBL17179600 | 0.78 | EPHA2 (0.52) | EPHA2KDREPHB4ENPP1ERBB2 | |
| SCHEMBL3132645 | 0.77 | EPHA2 (0.55) | EPHA2KDREPHB4ENPP1ERBB2 | |
| SCHEMBL1401721 | 0.77 | NSD2 (0.54) | EPHA2KDREPHB4ENPP1FLT1 | |
| SCHEMBL5437112 | 0.76 | ENPP1 (0.56) | EPHA2KDREPHB4ENPP1ERBB2 | |
| SCHEMBL3134760 | 0.76 | PIK3CD (0.56) | EPHA2EPHB4ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | EPHA2 2874/4885KDR 2580/4885EPHB4 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.